Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data

Zacks05-27

Shares of Merus N.V. MRUS rose 36.2% on Friday after management announced the publication of an abstract for the 2024 ASCO meeting on a mid-stage study evaluating the combination of its ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2438334098?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","is_english":true,"pubTime":"2024-05-27 23:37","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2438334098","market":"us","top_or_hot":-1,"title":"Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data","media":"Zacks","content":"<div>\n<p>Shares of Merus N.V. MRUS rose 36.2% on Friday after management announced the publication of an abstract for the 2024 ASCO meeting on a mid-stage study evaluating the combination of its ...</p>\n\n<a href=\"https://finance.yahoo.com/news/merus-mrus-surges-36-head-153700596.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-27 23:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/merus-mrus-surges-36-head-153700596.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Merus N.V. MRUS rose 36.2% on Friday after management announced the publication of an abstract for the 2024 ASCO meeting on a mid-stage study evaluating the combination of its ...</p>\n\n<a href=\"https://finance.yahoo.com/news/merus-mrus-surges-36-head-153700596.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0861579265.USD","symbol_name":"联博低波幅策略股票基金A","start_time":0,"source_url":"https://finance.yahoo.com/news/merus-mrus-surges-36-head-153700596.html","article_id":"2438334098","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2438334098","pubTimestamp":1716824220,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Shares of Merus N.V. MRUS rose 36.2% on Friday after management announced the publication of an abstract for the 2024 ASCO meeting on a mid-stage study evaluating the combination of its investigational antibody, petosemtamab and Merck’s blockbuster oncology drug Keytruda.As of the Nov 6, 2023 cut-off date, 26 patients had been treated, with 24 continuing with the therapy. With only 10 patients evaluable for response at the cut-off point, Merus reported a 60% response rate — including one confirmed response, two confirmed partial responses and three unconfirmed partial responses.Though treatment-emergent adverse events were reported in all patients , the combination therapy was well-tolerated by study participants. No significant overlapping toxicities were observed. While infusion-related reactions were reported in nearly 27% of patients, all occurred during the first infusion and were resolved.Management intends to hold a conference call on May 28 to discuss a more mature dataset from","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0861579265.USD":"联博低波幅策略股票基金A","HRTX":"Heron Therapeutics Inc.","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0122379950.USD":"贝莱德世界健康科学A2","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","MRUS":"Merus B.V.","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","MRK":"默沙东","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4534":"瑞士信贷持仓","LU0238689110.USD":"贝莱德环球动力股票基金","ARQT":"Arcutis Biotherapeutics Inc.","BK4533":"AQR资本管理(全球第二大对冲基金)","MRNS":"Marinus Pharmaceuticals","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4007":"制药","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999002232.USD":"Allianz Global High Payout USD","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU0058720904.USD":"联博国际健康护理基金A","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC"},"translate_title":"Merus（MRUS）头颈癌抗体数据飙升36%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARQT":1,"HRTX":1,"MRUS":1,"MRNS":0.9,"MRK":0.63},"content_text":"Shares of Merus N.V. MRUS rose 36.2% on Friday after management announced the publication of an abstract for the 2024 ASCO meeting on a mid-stage study evaluating the combination of its investigational antibody, petosemtamab and Merck’s blockbuster oncology drug Keytruda.\nThis study evaluated the petosemtamab/Keytruda combination as a first-line treatment for patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC).\nAs of the Nov 6, 2023 cut-off date, 26 patients had been treated, with 24 continuing with the therapy. With only 10 patients evaluable for response at the cut-off point, Merus reported a 60% response rate — including one confirmed response, two confirmed partial responses and three unconfirmed partial responses.\nThough treatment-emergent adverse events were reported in all patients (mostly grade 1 or 2 in severity), the combination therapy was well-tolerated by study participants. No significant overlapping toxicities were observed. While infusion-related reactions were reported in nearly 27% of patients, all occurred during the first infusion and were resolved.\nManagement intends to hold a conference call on May 28 to discuss a more mature dataset from the study at a later cut-off date ‘where the response rate further improved.’ It also intends to make a full presentation at the 2024 ASCO Annual Meeting on Jun 3.\nInvestors were likely impressed with the response rate, especially the one confirmed response, which was the likely reason for the soaring share price. In its press release, MRUS stated that these responses have since been confirmed, establishing this 60% as a confirmed response rate. Wall Street analysts were also impressed with the results, as William Blair was ‘highly encouraged’ with the data, while H.C. Wainwright called the results ‘impressive.’\nYear to date, Merus’ stock has skyrocketed 118.2% against the industry’s 5.7% fall.\nImage Source: Zacks Investment Research\nWith no marketed products in its portfolio, Merus is highly dependent on its pipeline for growth. Earlier this month, the FDA accepted the company’s regulatory filing seeking approval for zenocutuzumab to treat two NRG1 fusion-positive cancers — non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC). If approved, zenocutuzumab will be the first and only targeted therapy for patients with NRG1+ NSCLC and PDAC indications.\n\nMerus N.V. Price\n\nMerus N.V. price | Merus N.V. Quote\n\n \nZacks Rank & Key Picks\nMerus currently carries a Zacks Rank #3 (Buy). Some better-ranked stocks in the overall healthcare sector include Arcutis Biotherapeutics ARQT, Marinus Pharmaceuticals MRNS and Heron Therapeutics HRTX, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nIn the past 60 days, estimates for Arcutis Biotherapeutics’ 2024 loss per share have narrowed from $2.49 to $1.60. During the same period, the loss estimates per share for 2025 have improved from $1.77 to $1.14. Year to date, shares of Arcutis have surged 183.6%.\nEarnings of Arcutis Biotherapeutics beat estimates in three of the last four quarters while missing the mark on one occasion. Arcutis delivered a four-quarter average earnings surprise of 14.93%.\nIn the past 60 days, estimates for Marinus Pharmaceuticals’ 2024 loss per share have improved from $2.44 to $1.87. During the same period, loss estimates for 2025 have narrowed from $1.97 to 90 cents.\nEarnings of Marinus Pharmaceuticals beat estimates in two of the last four quarters and met the mark on one occasion while missing the mark on another. Marinus delivered a four-quarter average earnings surprise of 3.27%.\nIn the past 60 days, estimates for Heron Therapeutics’ 2024 loss per sharehave improved from 22 cents to 10 cents. During the same period, estimates for 2025 have improved from a loss of 9 cents to earnings of 1 cent. Year to date, HRTX’s shares have appreciated 102.4%.\nEarnings of Heron Therapeutics beat estimates in three of the last four quarters while missing the mark on one occasion. HRTX delivered a four-quarter average earnings surprise of 30.33%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nHeron Therapeutics, Inc. (HRTX) : Free Stock Analysis Report\nMarinus Pharmaceuticals, Inc. (MRNS) : Free Stock Analysis Report\nMerus N.V. (MRUS) : Free Stock Analysis Report\nArcutis Biotherapeutics, Inc. (ARQT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2438334098"}